Published in Br J Haematol on April 18, 2013
Vaso-occlusion in sickle cell disease: pathophysiology and novel targeted therapies. Blood (2013) 1.52
Synergies of phosphatidylserine and protein disulfide isomerase in tissue factor activation. Thromb Haemost (2014) 1.29
Neutrophils, platelets, and inflammatory pathways at the nexus of sickle cell disease pathophysiology. Blood (2016) 0.96
Endothelial activation by platelets from sickle cell anemia patients. PLoS One (2014) 0.83
Dietary ω-3 fatty acids protect against vasculopathy in a transgenic mouse model of sickle cell disease. Haematologica (2015) 0.82
Iron, inflammation, and early death in adults with sickle cell disease. Circ Res (2014) 0.82
Elevated hypercoagulability markers in hemoglobin SC disease. Haematologica (2015) 0.80
Plasma concentration of platelet-derived microparticles is related to painful vaso-occlusive phenotype severity in sickle cell anemia. PLoS One (2014) 0.80
Coagulation activation in sickle cell trait: an exploratory study. Br J Haematol (2015) 0.80
Coagulation abnormalities of sickle cell disease: Relationship with clinical outcomes and the effect of disease modifying therapies. Blood Rev (2015) 0.80
Genetic variants at HbF-modifier loci moderate anemia and leukocytosis in sickle cell disease in Tanzania. Am J Hematol (2014) 0.80
Preoperative blood transfusions for sickle cell disease. Cochrane Database Syst Rev (2016) 0.78
Abnormal Regulation of Microvascular Tone in a Murine Model of Sickle Cell Disease Assessed by Contrast Ultrasound. J Am Soc Echocardiogr (2015) 0.78
Role of innate immunity-triggered pathways in the pathogenesis of Sickle Cell Disease: a meta-analysis of gene expression studies. Sci Rep (2015) 0.77
Red blood cell transfusion to treat or prevent complications in sickle cell disease: an overview of Cochrane reviews. Cochrane Database Syst Rev (2016) 0.75
Progressing Preemptive Genotyping of CYP2C19 Allelic Variants for Sickle Cell Disease Patients. Genet Test Mol Biomarkers (2016) 0.75
Interventions for chronic kidney disease in people with sickle cell disease. Cochrane Database Syst Rev (2016) 0.75
Comment on "Influence of βS-globin haplotypes and hydroxyurea on tumor necrosis factor-alpha levels in sickle cell anemia". Rev Bras Hematol Hemoter (2014) 0.75
The design and synthesis of new synthetic low-molecular-weight heparins. J Thromb Haemost (2016) 0.75
Interventions for preventing silent cerebral infarcts in people with sickle cell disease. Cochrane Database Syst Rev (2016) 0.75
Quercetin reduces hydroxyurea induced cytotoxicity in immortalized mouse aortic endothelial cells. PeerJ (2017) 0.75
Interventions for preventing silent cerebral infarcts in people with sickle cell disease. Cochrane Database Syst Rev (2017) 0.75
Interventions for chronic kidney disease in people with sickle cell disease. Cochrane Database Syst Rev (2017) 0.75
Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. N Engl J Med (1995) 13.59
Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA (2003) 8.18
Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease. Nat Med (2002) 7.59
Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension, and mortality in sickle cell disease. JAMA (2005) 6.14
Sickle-cell disease. Lancet (2010) 5.64
Selective cellular expression of tissue factor in human tissues. Implications for disorders of hemostasis and thrombosis. Am J Pathol (1989) 5.41
Pathophysiology of ischaemia-reperfusion injury. J Pathol (2000) 5.18
ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions. Blood (2002) 4.52
Deconstructing sickle cell disease: reappraisal of the role of hemolysis in the development of clinical subphenotypes. Blood Rev (2006) 4.46
Transgenic knockout mice with exclusively human sickle hemoglobin and sickle cell disease. Science (1997) 4.25
Venous thromboembolism during pregnancy and the postpartum period: incidence, risk factors, and mortality. Am J Obstet Gynecol (2006) 3.08
Sickle blood contains tissue factor-positive microparticles derived from endothelial cells and monocytes. Blood (2003) 3.04
Tissue factor- and factor X-dependent activation of protease-activated receptor 2 by factor VIIa. Proc Natl Acad Sci U S A (2000) 3.01
Heterotypic interactions enabled by polarized neutrophil microdomains mediate thromboinflammatory injury. Nat Med (2009) 2.93
The endothelial biology of sickle cell disease: inflammation and a chronic vasculopathy. Microcirculation (2004) 2.88
Thrombogenesis in sickle cell disease. J Lab Clin Med (2001) 2.75
Acute chest syndrome in sickle cell disease: clinical presentation and course. Cooperative Study of Sickle Cell Disease. Blood (1997) 2.74
Primary role for adherent leukocytes in sickle cell vascular occlusion: a new paradigm. Proc Natl Acad Sci U S A (2002) 2.72
Role of the extrinsic pathway of blood coagulation in hemostasis and thrombosis. Arterioscler Thromb Vasc Biol (2007) 2.70
Leukocyte engagement of fibrin(ogen) via the integrin receptor alphaMbeta2/Mac-1 is critical for host inflammatory response in vivo. J Clin Invest (2004) 2.57
Sickle cell disease: old discoveries, new concepts, and future promise. J Clin Invest (2007) 2.47
Characterization of heme as activator of Toll-like receptor 4. J Biol Chem (2007) 2.38
The structural biology of expression and function of tissue factor. Thromb Haemost (1991) 2.28
Microparticles in hemostasis and thrombosis. Circ Res (2011) 2.26
Hematopoietic and nonhematopoietic cell tissue factor activates the coagulation cascade in endotoxemic mice. Blood (2010) 2.10
Activated monocytes in sickle cell disease: potential role in the activation of vascular endothelium and vaso-occlusion. Blood (2000) 2.10
Biologically active CD40 ligand is elevated in sickle cell anemia: potential role for platelet-mediated inflammation. Arterioscler Thromb Vasc Biol (2006) 2.06
Transgenic sickle mice have vascular inflammation. Blood (2003) 2.03
Correction of sickle cell disease by homologous recombination in embryonic stem cells. Blood (2006) 1.92
Localization of human tissue factor antigen by immunostaining with monospecific, polyclonal anti-human tissue factor antibody. Thromb Res (1990) 1.90
Heme is a potent inducer of inflammation in mice and is counteracted by heme oxygenase. Blood (2001) 1.88
Platelet- and erythrocyte-derived microparticles trigger thrombin generation via factor XIIa. J Thromb Haemost (2012) 1.86
The role of von Willebrand factor in thrombus formation. Thromb Res (2007) 1.85
Antiphospholipid antibodies, proteins C and S, and coagulation changes in sickle cell disease. J Lab Clin Med (1999) 1.82
Plasma concentrations of hemopexin, haptoglobin and heme in patients with various hemolytic diseases. Blood (1968) 1.81
Whole blood tissue factor procoagulant activity is elevated in patients with sickle cell disease. Blood (1998) 1.79
Sickle cell disease: the neurological complications. Ann Neurol (2002) 1.77
Endothelial cell expression of tissue factor in sickle mice is augmented by hypoxia/reoxygenation and inhibited by lovastatin. Blood (2004) 1.73
Initiation of coagulation by tissue factor. CRC Crit Rev Biochem (1988) 1.73
Chemical genetic strategy identifies histone deacetylase 1 (HDAC1) and HDAC2 as therapeutic targets in sickle cell disease. Proc Natl Acad Sci U S A (2010) 1.72
Oxidative modification of von Willebrand factor by neutrophil oxidants inhibits its cleavage by ADAMTS13. Blood (2009) 1.70
Tissue factor-factor VIIa signaling. Arterioscler Thromb Vasc Biol (2004) 1.69
NKT cells mediate pulmonary inflammation and dysfunction in murine sickle cell disease through production of IFN-gamma and CXCR3 chemokines. Blood (2009) 1.69
Deep venous thrombosis and pulmonary embolism in hospitalized patients with sickle cell disease. Am J Med (2006) 1.68
Coagulation activation and inflammation in sickle cell disease-associated pulmonary hypertension. Haematologica (2008) 1.67
The fibrin-derived peptide Bbeta15-42 protects the myocardium against ischemia-reperfusion injury. Nat Med (2005) 1.66
Inhibition of cell adhesion by anti-P-selectin aptamer: a new potential therapeutic agent for sickle cell disease. Blood (2010) 1.66
Pulmonary artery thrombosis during acute chest syndrome in sickle cell disease. Am J Respir Crit Care Med (2011) 1.66
Hypercoagulability in sickle cell disease: new approaches to an old problem. Hematology Am Soc Hematol Educ Program (2007) 1.65
D-dimer antigen: current concepts and future prospects. Blood (2008) 1.59
Tissue factor expression by endothelial cells in sickle cell anemia. J Clin Invest (1998) 1.58
Long-term anti-coagulation in sickle-cell disease. A clinical study. N Engl J Med (1963) 1.51
New anticoagulants. Circulation (2010) 1.48
Circulating erythrocyte-derived microparticles are associated with coagulation activation in sickle cell disease. Haematologica (2009) 1.46
Sickle cell vaso-occlusion: multistep and multicellular paradigm. Curr Opin Hematol (2002) 1.45
Differential contributions of monocyte- and platelet-derived microparticles towards thrombin generation and fibrin formation and stability. J Thromb Haemost (2011) 1.43
Thrombophilia in sickle cell disease: the red cell connection. Blood (2001) 1.39
Hypercoagulability and thrombotic complications in hemolytic anemias. Haematologica (2009) 1.36
Tissue factor-positive neutrophils bind to injured endothelial wall and initiate thrombus formation. Blood (2012) 1.34
New insights into the mechanisms of venous thrombosis. J Clin Invest (2012) 1.32
Thrombosis and sickle cell disease. Semin Thromb Hemost (2011) 1.32
Tissue factor-protease-activated receptor 2 signaling promotes diet-induced obesity and adipose inflammation. Nat Med (2011) 1.31
Sickle erythrocytes adhere to polymorphonuclear neutrophils and activate the neutrophil respiratory burst. Blood (1996) 1.31
Pulmonary thrombotic arteriopathy in patients with sickle cell disease. Arch Pathol Lab Med (2001) 1.31
Release of spectrin-free spicules on reoxygenation of sickled erythrocytes. Nature (1982) 1.31
Platelet activation in patients with sickle cell disease. Br J Haematol (1998) 1.29
Cytokine profile of sickle cell disease in Oman. Am J Hematol (2004) 1.28
Pathophysiology of stroke in sickle cell disease. Microcirculation (2004) 1.28
Role of tissue factor in haemostasis, thrombosis, angiogenesis and inflammation: lessons from low tissue factor mice. Thromb Haemost (2004) 1.28
Unusually large von Willebrand factor multimers increase adhesion of sickle erythrocytes to human endothelial cells under controlled flow. J Clin Invest (1987) 1.27
Mechanism for fetal hemoglobin induction by histone deacetylase inhibitors involves gamma-globin activation by CREB1 and ATF-2. Blood (2006) 1.27
The rate of hemolysis in sickle cell disease correlates with the quantity of active von Willebrand factor in the plasma. Blood (2011) 1.24
Heme induces the expression of adhesion molecules ICAM-1, VCAM-1, and E selectin in vascular endothelial cells. Proc Soc Exp Biol Med (1997) 1.24
Neutrophil activation by the tissue factor/Factor VIIa/PAR2 axis mediates fetal death in a mouse model of antiphospholipid syndrome. J Clin Invest (2008) 1.23
Heme induces neutrophil migration and reactive oxygen species generation through signaling pathways characteristic of chemotactic receptors. J Biol Chem (2007) 1.22
Fibrin(ogen)-alpha M beta 2 interactions regulate leukocyte function and innate immunity in vivo. Exp Biol Med (Maywood) (2004) 1.20
Neutrophil activation in sickle cell disease. J Leukoc Biol (1999) 1.19
Reduction of painful vaso-occlusive crisis of sickle cell anaemia by tinzaparin in a double-blind randomized trial. Thromb Haemost (2007) 1.18
Association of coagulation activation with clinical complications in sickle cell disease. PLoS One (2012) 1.17
P-selectin-mediated platelet-neutrophil aggregate formation activates neutrophils in mouse and human sickle cell disease. Arterioscler Thromb Vasc Biol (2010) 1.17
The contribution of endothelial cell P-selectin to the microvascular flow of mouse sickle erythrocytes in vivo. Blood (2004) 1.15
Haemoglobin blocks von Willebrand factor proteolysis by ADAMTS-13: a mechanism associated with sickle cell disease. Thromb Haemost (2009) 1.15
Heme induces endothelial tissue factor expression: potential role in hemostatic activation in patients with hemolytic anemia. J Thromb Haemost (2008) 1.14
Integrin alpha 4 beta 1 and glycoprotein IV (CD36) are expressed on circulating reticulocytes in sickle cell anemia. Blood (1993) 1.13
Sickle reticulocytes adhere to VCAM-1. Blood (1995) 1.13
Pulmonary changes in sickle cell disease. Am Rev Respir Dis (1971) 1.12
Pulmonary embolism in sickle cell disease: a case-control study. J Thromb Haemost (2012) 1.12
Sickle cell disease of transgenic SAD mice. Blood (1994) 1.12
Big strokes in small persons. Arch Neurol (2007) 1.10
Activated monocytes and platelet-monocyte aggregates in patients with sickle cell disease. Clin Lab Haematol (2002) 1.10
A potent oral P-selectin blocking agent improves microcirculatory blood flow and a marker of endothelial cell injury in patients with sickle cell disease. Am J Hematol (2012) 1.09
Uncoupling of the membrane skeleton from the lipid bilayer. The cause of accelerated phospholipid flip-flop leading to an enhanced procoagulant activity of sickled cells. J Clin Invest (1985) 1.08
A systems biology consideration of the vasculopathy of sickle cell anemia: the need for multi-modality chemo-prophylaxsis. Cardiovasc Hematol Disord Drug Targets (2009) 1.07
Platelets, coagulation, and fibrinolysis in sickle cell disease: their possible role in vascular occlusion. Blood Coagul Fibrinolysis (1991) 1.03
Inhaled nitric oxide protects transgenic SAD mice from sickle cell disease-specific lung injury induced by hypoxia/reoxygenation. Blood (2003) 1.02
A pilot study of the short-term use of simvastatin in sickle cell disease: effects on markers of vascular dysfunction. Br J Haematol (2011) 1.02
Platelet hyperactivity in sickle-cell disease: a consequence of hyposplenism. J Clin Pathol (1980) 1.02
Coagulation changes during the steady state in homozygous sickle-cell disease in Jamaica. Br J Haematol (1975) 1.02
Role of platelet P-selectin and CD40 ligand in the induction of monocytic tissue factor expression. Arterioscler Thromb Vasc Biol (2000) 1.00
HIF-1alpha is essential for myeloid cell-mediated inflammation. Cell (2003) 9.12
Dendritic cell PAR1-S1P3 signalling couples coagulation and inflammation. Nature (2008) 3.14
The thrombomodulin-protein C system is essential for the maintenance of pregnancy. Nat Med (2003) 1.98
Genetic analysis of the role of the PI3K-Akt pathway in lipopolysaccharide-induced cytokine and tissue factor gene expression in monocytes/macrophages. J Immunol (2008) 1.74
PI3K-Akt pathway suppresses coagulation and inflammation in endotoxemic mice. Arterioscler Thromb Vasc Biol (2004) 1.65
Factor Xa binding to annexin 2 mediates signal transduction via protease-activated receptor 1. Circ Res (2008) 1.55
Differential contribution of FXa and thrombin to vascular inflammation in a mouse model of sickle cell disease. Blood (2014) 1.53
PF4/heparin-antibody complex induces monocyte tissue factor expression and release of tissue factor positive microparticles by activation of FcγRI. Blood (2012) 1.48
A balance between tissue factor and tissue factor pathway inhibitor is required for embryonic development and hemostasis in adult mice. Blood (2004) 1.26
Tumor-derived tissue factor activates coagulation and enhances thrombosis in a mouse xenograft model of human pancreatic cancer. Blood (2012) 1.20
PAR-1 contributes to the innate immune response during viral infection. J Clin Invest (2013) 1.09
Protease-activated receptor 2 deficiency reduces cardiac ischemia/reperfusion injury. Arterioscler Thromb Vasc Biol (2010) 1.00
Protease-activated receptors and myocardial infarction. IUBMB Life (2011) 0.98
Protease-activated receptors mediate crosstalk between coagulation and fibrinolysis. Blood (2010) 0.95
Tissue factor promotes activation of coagulation and inflammation in a mouse model of sickle cell disease. Blood (2012) 0.93
Tissue factor expression provokes escape from tumor dormancy and leads to genomic alterations. Proc Natl Acad Sci U S A (2014) 0.91
Atherosclerosis in mice is not affected by a reduction in tissue factor expression. Arterioscler Thromb Vasc Biol (2005) 0.87
Protease activated receptor-2 contributes to heart failure. PLoS One (2013) 0.81
Dysregulated coagulation associated with hypofibrinogenaemia and plasma hypercoagulability: implications for identifying coagulopathic mechanisms in humans. Thromb Haemost (2012) 0.81
A non-anticoagulant synthetic pentasaccharide reduces inflammation in a murine model of kidney ischemia-reperfusion injury. Thromb Haemost (2006) 0.78
The contribution of tumor and host tissue factor expression to oncogene-driven gliomagenesis. Biochem Biophys Res Commun (2014) 0.78
Tissue factor and thrombin in sickle cell anemia. Thromb Res (2012) 0.78
De novo synthesis of a narrow size distribution low-molecular-weight heparin. Glycobiology (2014) 0.78
We can do it together: PAR1/PAR2 heterodimer signaling in VSMCs. Arterioscler Thromb Vasc Biol (2011) 0.77
Protease-Activated Receptor 1 Contributes to Angiotensin II-Induced Cardiovascular Remodeling and Inflammation. Cardiology (2016) 0.76